Search
lumasiran (Oxlumo)
Indications:
- treatment of primary hyperoxaluria type 1
Dosage:
- 0.5 mL lumasiran 189 mg/mL injection
Adverse effects:
- injection site reactions
- abdominal pain
Mechanism of action:
- double-stranded small interfering ribonucleic acid (siRNA)
- reduces levels of glycolate oxidase by targeting HAO1 mRNA in hepatocytes through RNA interference [2]
General
short interfering double-stranded RNA; antisense oligonucleotide (siRNA, microRNA, miRNA)
metabolic agent (metabolic modifier)
References
- RxNorm
- Wikipedia: Lumasiran
https://en.wikipedia.org/wiki/Lumasiran